Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKLR | P30613 | 2/20 | 1.00 |
| ▸ | PDE2A | O00408 | 1/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.61 |
| ▸ | ESR1 | P03372 | 4/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15423100 | 1.00 | PKLR (1.00) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL14294225 | 0.93 | PKLR (0.87) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL16663940 | 0.89 | PDE2A (0.85) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL803408 | 0.89 | PDE2A (1.00) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL29368885 | 0.89 | PDE2A (1.00) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL29401099 | 0.89 | PDE2A (1.00) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL26772728 | 0.89 | PKLR (0.79) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL26772481 | 0.89 | PKLR (0.79) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL26772733 | 0.89 | PKLR (0.79) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL26768208 | 0.89 | PKLR (0.79) | PKLRPDE2ANPSR1RXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 369 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104588-A1 | UROLITHIN COMBINATION | AMAZENTIS SA (CH) | 2026-05-21 | — | — | WO | claimed |
| US-12605360-B2 | Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-04-21 | — | — | US | claimed |
| US-20260090966-A1 | UROLITHIN COMPOSITIONS | AMAZENTIS SA (CH) | 2026-04-02 | — | — | US | claimed |
| EP-4712785-A1 | CHEWABLE COMPOSITIONS COMPRISING PECTIN AND UROLITHIN | Amazentis SA (CH) | 2026-03-25 | — | — | EP | claimed |
| US-20260069693-A1 | UROLITHINS AND T-CELL MEDIATED IMMUNE RESPONSE | CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG SPEYER HAUS (DE) | 2026-03-12 | — | — | US | claimed |
| US-20250375414-A1 | UROLITHIN COMBINATIONS | AMAZENTIS SA (CH) | 2025-12-11 | — | — | US | claimed |
| US-20250375415-A1 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | AMAZENTIS SA (CH) | 2025-12-11 | — | — | US | claimed |
| US-20250367159-A1 | UROLITHIN GUMMY (PECTIN) FORMULATIONS | AMAZENTIS SA (CH) | 2025-12-04 | — | — | US | claimed |
| US-20250367099-A1 | UROLITHIN COMBINATIONS | DAMICO DAVIDE (CH) | 2025-12-04 | — | — | US | claimed |
| EP-4395771-B1 | TREATING LONG COVID-19 WITH UROLITHINS | AMAZENTIS SA (CH) | 2025-11-19 | — | — | EP | claimed |
| US-20220267741-A1 | ENZYME CAPABLE OF DEHYDROXYLATING HYDROXYL GROUP IN UROLITHIN COMPOUND | DAICEL CORPORATION (JP) | 2022-08-25 | — | — | US | claimed |
| EP-3561067-B1 | METHOD FOR PRODUCING UROLITHINS | DAICEL CORP (JP) | 2022-08-03 | — | — | EP | claimed |
| CN-114760996-A | Direct AMPK activator compounds in combination with indirect AMPK activator compounds, compositions, methods, and uses thereof | 雀巢产品有限公司 | 2022-07-15 | — | — | CN | claimed |
| WO-2022115863-A1 | CHROMIUM ALLOY COATED NUCLEAR FUEL RODS | WESTINGHOUSE ELECTRIC COMPANY LLC (US) | 2022-06-02 | — | — | WO | claimed |
| EP-4006163-A1 | ENZYME CAPABLE OF DEHYDROXYLATING HYDROXYL GROUP IN UROLITHIN COMPOUND | Daicel Corporation (JP) | 2022-06-01 | — | — | EP | claimed |
| US-20220105117-A1 | COMPOSITIONS COMPRISING NICOTINAMIDE RIBOSIDE AND A UROLITHIN | AMAZENTIS SA (CH) | 2022-04-07 | — | — | US | claimed |
| WO-2022063846-A1 | COMPOSITIONS AND METHODS USING XANTHAN GUM TO STABILIZE AT LEAST ONE UROLITHIN IN AN AQUEOUS MATRIX | Société des Produits Nestlé S.A. (CH) | 2022-03-31 | — | — | WO | claimed |
| US-20220096433-A1 | COMPOSITIONS COMPRISING UROLITHINS AND USES THEREOF FOR THE STIMULATION OF INSULIN SECRETION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-03-31 | — | — | US | claimed |
| CN-114041531-A | Ellagic acid feed additive and application thereof | 中国农业大学 | 2022-02-15 | — | — | CN | claimed |
| US-20220044830-A1 | COATED FUEL PELLETS, METHODS OF MAKING AND USING SAME | UCHICAGO ARGONNE, LLC | 2022-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260090966-A1 | UROLITHIN COMPOSITIONS | UTS2R, TAS2R30, TAS2R42 | PKLR 4699/4885PDE2A 688/4885NPSR1 3978/4885 |
| US-20260069693-A1 | UROLITHINS AND T-CELL MEDIATED IMMUNE RESPONSE | MAVS, TFAM, MCU | PKLR 3874/4885PDE2A 4316/4885NPSR1 3647/4885 |
| US-20250375414-A1 | UROLITHIN COMBINATIONS | AHCY, BHMT, BHMT2 | PKLR 3073/4885PDE2A 1581/4885NPSR1 3769/4885 |
| US-20220105117-A1 | COMPOSITIONS COMPRISING NICOTINAMIDE RIBOSIDE AND A UROLITHIN | NNT, UQCRC1, UQCRC2 | PKLR 2582/4885PDE2A 2684/4885NPSR1 3567/4885 |
| US-20250367099-A1 | UROLITHIN COMBINATIONS | ASAH2, HEXB, SGMS2 | PKLR 478/4885PDE2A 2314/4885NPSR1 3018/4885 |
| US-20250367159-A1 | UROLITHIN GUMMY (PECTIN) FORMULATIONS | PYGM, GALE, GYS1 | PKLR 537/4885PDE2A 265/4885NPSR1 4548/4885 |
| US-20250375415-A1 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | ATG7, BECN1, ATG4A | PKLR 2562/4885PDE2A 2005/4885NPSR1 4309/4885 |
| US-12605360-B2 | Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix | LGALS9, PLAU, TAS2R19 | PKLR 1846/4885PDE2A 772/4885NPSR1 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.